Cargando…
Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis
BACKGROUND: The treatment of choice for desmoid‐type fibromatosis (DF) has been changed to active surveillance (AS). However, few studies have reported clinical outcomes of AS modality in Asian countries. This study aimed to clarify the significance of AS as a DF treatment modality. METHODS: A total...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028109/ https://www.ncbi.nlm.nih.gov/pubmed/36210645 http://dx.doi.org/10.1002/cam4.5329 |
_version_ | 1784909869621444608 |
---|---|
author | Sakai, Tomohisa Nishida, Yoshihiro Ito, Kan Ikuta, Kunihiro Urakawa, Hiroshi Koike, Hiroshi Imagama, Shiro |
author_facet | Sakai, Tomohisa Nishida, Yoshihiro Ito, Kan Ikuta, Kunihiro Urakawa, Hiroshi Koike, Hiroshi Imagama, Shiro |
author_sort | Sakai, Tomohisa |
collection | PubMed |
description | BACKGROUND: The treatment of choice for desmoid‐type fibromatosis (DF) has been changed to active surveillance (AS). However, few studies have reported clinical outcomes of AS modality in Asian countries. This study aimed to clarify the significance of AS as a DF treatment modality. METHODS: A total of 168 lesions from 162 patients with extra‐abdominal DF were included. The mean age at diagnosis was 39 years (1–88 years), and the median maximum tumor diameter at the first visit was 64.1 mm (13.2–255.8 mm). The clinical outcomes of AS and the risk factors requiring active treatment (AT) (defined as an event) from AS modality were investigated. RESULTS: Of the 168 lesions, 94 (56%) were able to continue AS, with a 5‐year event‐free survival of 54.8%. Of the 68 lesions with PD, 21 (30.9%) lesions were able to continue AS. Neck location (p = 0.043) and CTNNB1 S45F mutation (p = 0.003) were significantly associated with the transition to AT, and S45F mutation was a significant factor associated with the transition to AT by multivariate analysis (hazard ratio: 1.96, p = 0.048). AT outcomes after AS were evaluable in 65 lesions, and 49 (75%) lesions did not require a transition to a second AT. CONCLUSIONS: AS was revealed as an effective treatment modality. The transition to AT needs to be considered for neck location and CTNNB1 S45F mutation DF. Good results can be obtained by selecting a treatment method that considers the tumor location even in cases that require intervention. |
format | Online Article Text |
id | pubmed-10028109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100281092023-03-22 Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis Sakai, Tomohisa Nishida, Yoshihiro Ito, Kan Ikuta, Kunihiro Urakawa, Hiroshi Koike, Hiroshi Imagama, Shiro Cancer Med RESEARCH ARTICLES BACKGROUND: The treatment of choice for desmoid‐type fibromatosis (DF) has been changed to active surveillance (AS). However, few studies have reported clinical outcomes of AS modality in Asian countries. This study aimed to clarify the significance of AS as a DF treatment modality. METHODS: A total of 168 lesions from 162 patients with extra‐abdominal DF were included. The mean age at diagnosis was 39 years (1–88 years), and the median maximum tumor diameter at the first visit was 64.1 mm (13.2–255.8 mm). The clinical outcomes of AS and the risk factors requiring active treatment (AT) (defined as an event) from AS modality were investigated. RESULTS: Of the 168 lesions, 94 (56%) were able to continue AS, with a 5‐year event‐free survival of 54.8%. Of the 68 lesions with PD, 21 (30.9%) lesions were able to continue AS. Neck location (p = 0.043) and CTNNB1 S45F mutation (p = 0.003) were significantly associated with the transition to AT, and S45F mutation was a significant factor associated with the transition to AT by multivariate analysis (hazard ratio: 1.96, p = 0.048). AT outcomes after AS were evaluable in 65 lesions, and 49 (75%) lesions did not require a transition to a second AT. CONCLUSIONS: AS was revealed as an effective treatment modality. The transition to AT needs to be considered for neck location and CTNNB1 S45F mutation DF. Good results can be obtained by selecting a treatment method that considers the tumor location even in cases that require intervention. John Wiley and Sons Inc. 2022-10-09 /pmc/articles/PMC10028109/ /pubmed/36210645 http://dx.doi.org/10.1002/cam4.5329 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Sakai, Tomohisa Nishida, Yoshihiro Ito, Kan Ikuta, Kunihiro Urakawa, Hiroshi Koike, Hiroshi Imagama, Shiro Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis |
title | Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis |
title_full | Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis |
title_fullStr | Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis |
title_full_unstemmed | Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis |
title_short | Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis |
title_sort | clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028109/ https://www.ncbi.nlm.nih.gov/pubmed/36210645 http://dx.doi.org/10.1002/cam4.5329 |
work_keys_str_mv | AT sakaitomohisa clinicalresultsofactivesurveillanceforextraabdominaldesmoidtypefibromatosis AT nishidayoshihiro clinicalresultsofactivesurveillanceforextraabdominaldesmoidtypefibromatosis AT itokan clinicalresultsofactivesurveillanceforextraabdominaldesmoidtypefibromatosis AT ikutakunihiro clinicalresultsofactivesurveillanceforextraabdominaldesmoidtypefibromatosis AT urakawahiroshi clinicalresultsofactivesurveillanceforextraabdominaldesmoidtypefibromatosis AT koikehiroshi clinicalresultsofactivesurveillanceforextraabdominaldesmoidtypefibromatosis AT imagamashiro clinicalresultsofactivesurveillanceforextraabdominaldesmoidtypefibromatosis |